Our collaboration partner SB Drug Discovery is offering Services on Nanion's Instruments
SB Drug Discovery is a specialist ion channel CRO offering the most comprehensive portfolio of ion channel cell lines and screening assays for drug discovery research. SB’s extensive panel comprises more than 150 ion channel targets and over 200 ion channel assays covering a broad range of ion channel families. Their validated assays utilize fluorescence, manual patch clamp and automated electrophysiology platforms and can be customized to meet individual customer needs.
Whether you require HTS or routine lead optimization for your target of interest or selectivity profiling using a standard or customized panel of your choice for safety liabilities, SB’s expert team of Project Leaders, electrophysiologists and highly experienced scientists are on hand to design and manage your ion channel projects.
SB also specialises in custom ion channel cell line generation including generation of multi-target cell lines and species orthologs. Their cell biology team has extensive expertise in cell line generation and has optimised streamline processes to enable rapid generation of high quality ion channel reagents.
SB Drug Discovery services include:
- High throughput ion channel screening (automated electrophysiology). This service is offered on Nanion's SyncroPatch 384PE.
- High throughput ion channel screening (fluorescence-based)
- Routine profiling & selectivity panels
- hERG screening & cardiac profiling
- Manual patch clamp electrophysiology
Collaborative Activities and projects with SB Drug Discovery
NaV1.5 and hERG - "There is no F in APC: Reliable fluoride-free recordings on the SyncroPatch 384"
SyncroPatch 384 application note: 
(1.6 MB)
Cells were kindly provided by SB Drug Discovery and Charles River.
2021 - Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series
SyncroPatch 384 Publication in ACS Medicinal Chemistry Letters (2021)
Authors:
Griffin A. M., Kahlig K. M., Hatch R. J., Hughes Z. A., Chapman M. L., Antonio B., Marron B. E., Wittmann M., Martinez-Botella G.
2022 - The suitability of high throughput automated patch clamp for physiological applications
SyncroPatch 384 Publication in The Journal of Physiology (2022)
Authors:
Obergrussberger A., Rinke-Weiß I., Goetze T.A., Rapedius M., Brinkwirth N., Becker N., Rotordam M.G., Hutchison L., Madau P, Pau D, Dalrymple D., Braun N., Friis S., Pless S.A., Fertig N.
TASK-1 - "Activation and Inhibition of TASK-1 on Nanion’s SyncroPatch 384PE"
SyncroPatch 384PE (a predecessor model of SyncroPatch 384) application note: (3.1 MB)
Cells were kindly provided by SB Drug Discovery.
2020 - Ion Channels and Relevant Drug Screening Approaches
SyncroPatch 384i editorial found in SLAS Discovery (2020)
Authors:
McGivern, J.G., Ding M.
nAChRα4β2 - "Pharmacology of human α4β2 nAChR recorded on the SyncroPatch 384PE"
SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note: (0.8 MB)
Cells were engineered and kindly provided by SB Drug Discovery.
hERG - Application of Dofetilide
Port-a-Patch mini data and applications:
Cells were kindly provided by SB Drug Discovery.
Raw data traces of hERG (expressed in HEK cells) in control solution and in the presence of increasing concentrations of Dofetilide (top). IC50 concentration response curve for an average of 3 cells is shown revealing an IC50 of 161 ± 12 nM.
2018 - Expression and pharmacology of GluA2-containing AMPA receptors in cell lines and stem cell-derived neurons
Port-a-Patch, 
Patchliner and SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) poster, Europhysiology Meeting 2018 (0.9 MB)
2017 - lnvestigation of the Ion Channels hTMEM16A/Ano1 and TRPC5 and their Modulation by Intracellular Calcium
SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) poster, BPS Meeting 2017 (1.3 MB)
AMPA receptor (GluA2) - "Activation, potentiation and inhibition of AMPA receptors on the SyncroPatch 384PE"
SyncroPatch 384PE (a predecessor model of SyncroPatch 384) application note: (3.1 MB)
Cells were kindly provided by SB Drug Discovery.
AMPA Receptor (GluA2) - Pharmacology
SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
Cells were kindly provided by SB Drug Discovery.
The AMPA receptor (GluA2) was analyzed using different positive and negative allosteric modulators (CNQX, LY404187, LY395153, CP465022, Cyclothiazide). After activating the receptor by application of Glutamate, the modulating compound plus glutamate was applied afterwards. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384), the whole cell patch methodology and multi-hole chips were used.
The lower images on the left hand side are displaying a screenshot of a current after application of the positive modulator LY404187. The EC50 was determined as 379 nM.
AMPA Receptor (GluA2) - Activation by Glutamate
SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
Cells were kindly provided by SB Drug Discovery.
The AMPA receptor (GluA2) was activated using different concentrations of glutamate (1 µM - 100 µM). Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384), the whole cell patch methodology and multi-hole chips were used.
The lower two images are displaying screenshots of single cell currents after repetitive glutamate applications:
Left: The same concentration of Glutamate was applied three times.
Right: Four different Glutamate concentrations were applied in a cumulative manner.
AMPA Receptor (GluA2) - Cumulative Concentration Response
SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
Cells were kindly provided by SB Drug Discovery.
The AMPA receptor (GluA2)was activated by increasing concentrations of glutamate on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384). L-glutamate was applied for approximately 500 ms in increasing concentrations (A) and a cumulative concentration response curve for glutamate was constructed for 222 wells (C).
The online analysis values peak amplitude and area under the curve (AUC) are shown versus time in Panel B. The fast activation of GluA2 could be captured at higher concentrations (inset; 1 mM).
AMPA Receptor (GluA2) - Inhibition by CNQX
Patchliner data and applications:
Cells were kindly provided by SB Drug Discovery.
The AMPA receptor (GluA2) was blocked by CNQX on the Patchliner. CNQX was pre-incubated and then co-applied with glutamate. CNQX blocked the GluA2-mediated response in a concentration dependent manner and the potency was dependent on glutamate concentration (left). Exemplar GluA2-mediated responses are shown on the right activated by 100 µM glutamate and inhibited by increasing concentrations of CNQX.
AMPA Receptor (GluA2) - Reproducible Responses
Port-a-Patch data and applications:
Cells were kindly provided by SB Drug Discovery.
GluA2 reproducibly recorded on the Port-a-Patch. L-glutamate was applied for 500 ms and this was repeated six times in the same cell showing reproducible responses.
AMPA Receptor (GluA2) - Fast Perfusion with the Port-a-Patch
Port-a-Patch data and applications:
Cells were kindly provided by SB Drug Discovery.
The AMPA receptor (GluA2) was activated by increasing concentrations of glutamate on the Port-a-Patch. L-glutamate was applied for approximately 500 ms in increasing concentrations (left) and a cumulative concentration response curve for glutamate was constructed for 8 cells (right). The fast activation of GluA2 could be captured at higher concentrations (inset; 1 mM).
Dr. David Dalrymple - Statement about the SyncroPatch 384PE
“As a leading ion channel contract research organization running one of the most comprehensive ranges of ion channel assays, SB Drug Discovery has been impressed with the flexibility and reliability of the SyncroPatch 384PE (a predecessor model of SyncroPatch 384i), enabling development of a range of varied and complex ion channel assay for both high throughput screening and hit-to-lead profiling purposes. The SyncroPatch has proven to be a crucial addition to SB’s ion channel capabilities and in partnership with expert advice from Nanion’s support team has enabled SB to advance its ion channel capabilities to the forefront of ion channel drug discovery research..“
Dr. David Dalrymple
Business Development Director at SB Drug Discovery
TMEM16A (ANO1) - "Internal perfusion of Ca2+ to activate TMEM16A/ANO1 on the SyncroPatch 384PE"
SyncroPatch 384PE (a predecessor model of SyncroPatch 384) application note (1.1 MB)
Cells were kindly provided by SB Drug Discovery.
TREK-1 - "Activation and inhibition of TREK-1 on Nanion’s SyncroPatch 384PE"
SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note (6.0 MB)
Cells were kindly provided by SB Drug Discovery.
CaV1.2 - "High Throughput Pharmacology of CaV1.2 Channels on Nanion’s SyncroPatch 384PE"
SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) application note: (2.7 MB)
Cells were kindly provided by SB Drug Discovery.
